Publications by authors named "D Gijon"
[This corrects the article DOI: 10.3389/fmicb.2022.
View Article and Find Full Text PDFArticle Synopsis
- The study aims to assess the effectiveness of cefiderocol and other antibiotics against multi-drug resistant (MDR) Gram-negative bacteria, especially carbapenem-resistant strains, in Spain and Portugal.
- A total of 477 clinical isolates were evaluated, with susceptibility testing revealing that cefiderocol was highly effective, showing 99.5% susceptibility against Enterobacterales and excellent performance against other pathogens like Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
- The findings support previous research indicating that cefiderocol is a promising treatment option for infections caused by MDR Gram-negative bacteria, providing an alternative to existing antibiotics.
Objectives: To assess the microbiological characteristics of Escherichia coli causing healthcare-associated bacteraemia of urinary origin (HCA-BUO) in Spain (ITUBRAS-2 project), with particular focus on ESBL producers and isolates belonging to ST131 high-risk clone (HiRC). Clinical characteristics and outcomes associated with ST131 infection were investigated.
Methods: A total of 222 E.
The Enterobacter cloacae complex (ECC) encompasses heterogeneous clusters of species that have been associated with nosocomial outbreaks. These species may have different acquired antimicrobial resistance and virulence mechanisms, and their identification is challenging. This study aims to develop predictive models based on matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) profiles and machine learning for species-level identification.
View Article and Find Full Text PDFObjectives: To evaluate the activity of meropenem-amikacin and meropenem-colistin combinations with checkerboard broth microdilution (CKBM) compared with isothermal microcalorimetry (ITMC) assays against a multi-centric collection of multi-drug-resistant Gram-negative clinical isolates; and to compare the fractional inhibitory concentration (FIC) index and time to results of CKBM and ITMC.
Methods: A collection of 333 multi-drug-resistant Gram-negative clinical isolates showing reduced susceptibility to meropenem (121 Klebsiella pneumoniae, 14 Escherichia coli, 130 Pseudomonas aeruginosa and 68 Acinetobacter baumannii) isolated from different centres (Florence, Madrid, Rotterdam and Stockholm) was included in the study. The antimicrobial activity of meropenem-amikacin and meropenem-colistin combinations was evaluated with CKBM and ITMC.